Regulatory Impact on JAK Inhibitors Development

This document is a technical report that outlines the regulatory journey of Janus kinase (JAK) inhibitors, which have been significant in the treatment of various autoimmune conditions. Initially recognized for their breakthrough mechanism of action, JAK inhibitors faced a major setback in 2021 when the U.S. FDA issued class-wide boxed warnings due to safety concerns, including increased risks of cardiovascular events and malignancies. This regulatory change led to a decline in new program initiations in 2022, reflecting a cautious approach from sponsors. However, in 2023, there was a temporary resurgence in JAK inhibitor programs, particularly in dermatology, driven by recent approvals. Despite this, the overall trend indicates a fragile confidence in the class, with a marked decline in new program starts anticipated by 2024. The report emphasizes the need for strategic clarity and forward-looking visibility for portfolio managers and clinical strategy leads in navigating the evolving landscape of JAK inhibitors.